Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healthcare Biotechnology
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Healios KK Ord Shs
Bullboard Posts
User Avatar Image
(0)
•••
Comment by techrsvpon Jan 26, 2005 12:16pm
249 Views
Post# 8490854

RE: bachelor lake why pay $1++ get it for 65-70 c

RE: bachelor lake why pay $1++ get it for 65-70 cMetanor is still the operator and doesnt have to spend to earn its 50% and they also have TWO other properties,all i am saying if halo price goes up because of bachelor then so will MTO but you can get 1.5 shares for every share of halo,remember MTO & HLO are partners and there is gold in that mine and a lot more when you drill deeper,Mto doesnt have the big promoters that hlo has but being 50-50 they will eventually trade together,at .65,you cant go wrong.Bachelor is a great property
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities